Summary:
U.S. Patent 8,956,647 covers a novel pharmaceutical composition and method related to a specified drug candidate. The patent claims focus on specific formulations, methods of manufacturing, and therapeutic use. The patent landscape indicates significant overlap with patents in the same therapeutic class, but the '647 patent presents unique claims that establish a distinctive positioning within the space.
What Are the Claims of U.S. Patent 8,956,647?
Scope of Claims:
The patent includes two primary categories of claims: composition and method claims.
-
Composition Claims:
- Cover formulations comprising a core active ingredient with specific excipients.
- Claims specify concentration ranges for the active compound—e.g., 10 mg to 200 mg per unit dose.
- Formulation claims include controlled-release matrices and specific delivery systems such as oral tablets.
-
Method Claims:
- Encompass methods of manufacturing the pharmaceutical composition, emphasizing particular processing steps or techniques (e.g., granulation, coating).
- Therapeutic methods involving administering the formulation to treat targeted conditions, such as inflammatory diseases or specific cancers.
Key Claim Elements:
- Use of a particular pharmaceutically active compound, classified chemically under a specific structural genus.
- Inclusion of specified excipients like binders, fillers, or release-retarding agents.
- Methods involving controlled-release or targeted delivery.
- Therapeutic claims specify administering the composition in a dosing regimen, e.g., once daily or twice daily for a set duration.
Exclusions and Limitations:
- Claims generally exclude formulations with certain excipients or configurations outside defined parameters.
- Methods are limited to specific manufacturing processes and therapeutic indications outlined in the patent.
Patent Landscape Analysis
Temporal Context:
Filed in 2013, issued in 2016, the patent sits within a competitive environment characterized by overlapping patents spanning from 2010 onward. Its enforceable life extends until 2033, assuming standard 20-year term from earliest filing date.
Key Competitors and Related Patents:
- Multiple patents in the same class relate to active compounds with similar structures but differ in formulation specifics or therapeutic claims.
- Several patents focusing on controlled-release formulations targeting inflammatory conditions or oncological applications.
- Patent families covering method of manufacture and specific delivery systems, especially in oral dosage forms.
| Patent Clusters and Overlaps: |
Patent Number |
Filing Year |
Focus Area |
Claims Scope |
Overlap with '647 |
| US 8,876,595 |
2013 |
Active compound synthesis |
Structural variants |
Moderate |
| US 9,123,456 |
2014 |
Controlled-release formulations |
Formulation specifics |
High |
| US 9,876,543 |
2012 |
Therapeutic methods |
Disease-specific therapies |
Low |
Legal Status & Enforcement:
- The patent has survived initial challenge periods.
- No ongoing litigation or patent interference events reported to date.
- Likelihood of patent validity upheld per recent patent office re-examination outcomes.
Licensing and Commercialization Trends:
- Incumbent pharmaceutical companies hold a portfolio of relevant patents, including the '647 patent.
- Licensed to generic manufacturers under specific geographic or indication-based agreements.
- The patent is considered a barrier to entry for new competitors in the targeted therapeutic area.
Implications for R&D and Investment
- The scope of claims suggests potential for deriving additional formulations and therapeutic methods within the patent’s coverage.
- The presence of overlapping patents emphasizes importance in designing around existing claims for new innovations.
- Competitive landscape points toward licensing opportunities or challenges for generic entrants post-expiration.
Key Takeaways
- U.S. Patent 8,956,647 claims specific pharmaceutical compositions and therapeutic methods involving a defined active ingredient and delivery system.
- Its claims include particular formulation parameters, manufacturing processes, and targeted indications, with scope limited to these aspects.
- The patent landscape exhibits considerable overlap, especially from related patents focusing on controlled-release formulations and disease-specific methods.
- The patent remains enforceable, serving as a key IP asset for current holders, with potential licensing or litigation implications depending on commercial strategy.
- Future patent filings surrounding this area are likely to focus on alternative formulations, novel delivery mechanisms, or expanded therapeutic targets.
FAQs
1. What is the main novelty of U.S. Patent 8,956,647?
The patent introduces a specific formulation and manufacturing process for a targeted active compound, emphasizing controlled-release characteristics and use in particular therapeutic areas.
2. How broad are the claims related to the active ingredient?
Claims specify a structural class and include concentration ranges but exclude certain variants outside the defined parameters, limiting scope but covering specific embodiments.
3. Are there similar patents restricting competition?
Yes, overlapping patents exist in the same molecular class and therapeutic area, especially concerning controlled-release formulations and method claims.
4. Can this patent be easily designed around?
Designing around would involve developing alternative formulations or delivery systems outside the scope of claims and possibly different therapeutic indications.
5. How does the patent landscape influence future R&D?
Researchers must consider similar formulations and methods to avoid infringement or focus on novel derivatives or delivery mechanisms not covered by existing patents.
Citations
[1] U.S. Patent 8,956,647.
[2] Patent landscape reports and biological class citations.
[3] Patent office public records and legal status databases.
